Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis
Erythropoietin (EPO) acts as a neuroprotective factor and is upregulated after neuronal injury. It has been reported that in cerebrospinal fluid (CSF) of amyotrophic lateral sclerosis (ALS) patients, the EPO concentration is decreased. In this study, EPO levels in serum and CSF of 30 patients with ALS and in 15 controls, using an ELISA technique, were estimated. EPO level in serum was decreased, especially in patients with bulbar onset ALS. A trend toward a progressive EPO decline with the duration of the disease in the mild + moderate ALS cases was observed. In severe cases, a tendency towards a positive correlation of EPO and duration of the disease was present. Serum EPO values were age related only in mild + moderate ALS in patients below 40 years of age. In CSF, the EPO levels were significantly decreased. Lower EPO values in the bulbar onset ALS when compared with the spinal onset ALS were present. The EPO decrease did not correlate with the severity and duration of the disease. Age relation of the EPO level only in the mild + moderate ALS cases more than 40 years was present. Lack of differences in EPO levels between patients with ALS of rapid and slow progression indicates that EPO concentration cannot be used as a prognostic factor. Nevertheless, the decreased serum and CSF EPO concentration and the known EPO neuroprotective action may indicate that EPO administration can be a new promising therapeutic approach in ALS.
KeywordsAmyotrophic lateral sclerosis Erythropoietin Cerebrospinal fluid Serum
The study protocol was approved by the Bioethics Committee for Human Research of Medical University of Warsaw. All patients received information about the study and gave written personal consent for participation.
- Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Grasso G, Corica F, Frisina N (2002) Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci (Lond) 103:275–282Google Scholar
- Felgenhauer K (1995) The filtration concept of the blood-brain barrier as basis for the differentiation of CSF proteins. In: Greenwood J et al (eds) New concepts of a blood–brain barrier. Plenum, London, pp 209–217Google Scholar
- Just N, Moreau C, Lassalle P, Gosset P, Perez T, Brunaud-Danel V, Wallaert B, Destėe A, Defebvre L, Tonnel AB, Devos D (2007) High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromusc Disord 17:169–173CrossRefPubMedGoogle Scholar
- Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, Antozzi C, Ciano C, Beretta P, Caldiroli D, Ghelma F, Ferrara G, Ghezzi P (2009) Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 29:1–6CrossRefGoogle Scholar
- Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heuman R, CeramiA Ehrenreich H, Ghezzi P (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98:4044–4049CrossRefPubMedGoogle Scholar
- Thompson EJ (1988) The CSF proteins: a biochemical approach. Elsevier Sci Publ BV, Amsterdam, pp 67–85Google Scholar